Nautilus Biotechnology Reports Q3 2026 Results and Raises Annual Revenue Guidance
Nautilus Biotechnology (NAUT) reported third-quarter 2026 revenue of $234,000, driven primarily by grant funding from The Michael J. Fox Foundation for alpha-synuclein assay development. Despite a net loss of $15.6 million due to rising operating expenses in personnel and R&D, the company raised its full-year 2026 revenue guidance to exceed $500,000. The company is focused on scaling its proteoform assay pipeline, targeting 20 assays by mid-2028. Commercialization efforts are underway with instrument shipments and consumable kits for Tau and AKT1 scheduled for mid-2027. Management highlighted that their highly reproducible data aims to serve as a foundational training set for biological AI models. With $114.3 million in cash and equivalents, Nautilus maintains a financial runway extending into early 2028. However, leadership noted potential headwinds regarding customer sensitivity toward the timing of government-funded instrument purchases.
Tickers: $NAUT
Topics: Cash Position Financial Guidance Net Loss R&D Expenses Revenue Growth
Read the full article at Motley Fool
Part of the story Equinix Reports Strong Q3 2026 Results and Raises Full-Year Guidance (49 articles)